PMID- 34014122
OWN - NLM
STAT- MEDLINE
DCOM- 20211206
LR  - 20211214
IS  - 1532-2513 (Electronic)
IS  - 0892-3973 (Linking)
VI  - 43
IP  - 3
DP  - 2021 Jun
TI  - The efficacy and safety of Nivolumab combined with Ipilimumab in the 
      immunotherapy of cancer: a meta-analysis.
PG  - 386-394
LID - 10.1080/08923973.2021.1924195 [doi]
AB  - Background and Objective: Nivolumab and Ipilimumab are immune checkpoint 
      inhibitors. The combination of Nivolumab and Ipilimumab has been reported to have 
      complementary effects in the treatment of metastatic melanoma. The combination 
      therapy of Nivolumab and Ipilimumab (N+I) has shown synergistic effects in cancer 
      immunotherapy but this is still controversial due to the higher incidence of 
      toxicity. Hence, we conducted a meta-analysis to evaluate the efficacy and safety 
      profile of Nivolumab combined with Ipilimumab and compared the different dosing 
      schedules of the N+I combination.Methods: By searching in PubMed, PMC, Cochrane 
      library and major conference abstracts, eligible sixteen studies including N+I 
      therapy and Nivolumab monotherapy were selected to analyze overall response rate 
      (ORR), progression-free survival (PFS), overall survival (OS), and high-grade 
      (3-4) adverse effects (AEs). Results: Compared with monotherapy of Nivolumab, N+I 
      significantly improved ORR (RR=1.40 [95% CI 1.27, 1.54], P<0.00001) and PFS 
      (Hazard Ratio (HR)=0.83 [95% CI 0.77, 0.90], P<0.00001), but not OS (HR=0.93 [95% 
      CI 0.84, 1.03], P=0.16). In a sub-analysis, the combination of Nivolumab 1mg/kg 
      plus Ipilimumab 3mg/kg (N1I3) and Nivolumab 3mg/kg plus Ipilimumab 1mg/kg (N3I1) 
      achieved better ORR and PFS than Nivolumab 3mg/kg (N3) alone. Remarkably, OS was 
      also prolonged with the N1I3 combination compared with the N3I1 combination or 
      N3. Furthermore, a higher incidence of high-grade AEs also occurred with the 
      combination therapy of N1I3.Conclusions: N+I combination therapy showed greater 
      ORR and PFS compared with Nivolumab monotherapy. N1I3 combination provided the 
      benefit of ORR, PFS and OS but was associated with a higher incidence of 
      toxicity.
FAU - Xu, Yao
AU  - Xu Y
AD  - Sanhome-CPU Joint Laboratory, China Pharmaceutical University, Nanjing, PR China.
AD  - Antibody Engineering Laboratory, School of Life Science & Technology, China 
      Pharmaceutical University, Nanjing, PR China.
FAU - Hezam, Kamal
AU  - Hezam K
AD  - Antibody Engineering Laboratory, School of Life Science & Technology, China 
      Pharmaceutical University, Nanjing, PR China.
AD  - Nankai University School of Medicine, Tianjin, PR China.
AD  - Faculty of Applied Science, Taiz University, Taiz, Yemen.
FAU - Ali, Manasik Gumah
AU  - Ali MG
AD  - Antibody Engineering Laboratory, School of Life Science & Technology, China 
      Pharmaceutical University, Nanjing, PR China.
FAU - Wang, Yang
AU  - Wang Y
AD  - Institute of Immunotherapy, Fujian Medical University, Minhou County, Fuzhou, 
      China.
FAU - Zhang, Juan
AU  - Zhang J
AD  - Antibody Engineering Laboratory, School of Life Science & Technology, China 
      Pharmaceutical University, Nanjing, PR China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PT  - Video-Audio Media
DEP - 20210520
PL  - England
TA  - Immunopharmacol Immunotoxicol
JT  - Immunopharmacology and immunotoxicology
JID - 8800150
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Ipilimumab)
RN  - 31YO63LBSN (Nivolumab)
SB  - IM
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Humans
MH  - Immune Checkpoint Inhibitors/therapeutic use
MH  - *Immunotherapy
MH  - Ipilimumab/therapeutic use
MH  - *Melanoma/immunology/mortality/therapy
MH  - Nivolumab/therapeutic use
MH  - Progression-Free Survival
MH  - Survival Rate
OTO - NOTNLM
OT  - Cancer immunotherapy
OT  - Ipilimumab
OT  - Nivolumab
OT  - combination therapy
OT  - meta-analysis
EDAT- 2021/05/21 06:00
MHDA- 2021/12/15 06:00
CRDT- 2021/05/20 12:17
PHST- 2021/05/21 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2021/05/20 12:17 [entrez]
AID - 10.1080/08923973.2021.1924195 [doi]
PST - ppublish
SO  - Immunopharmacol Immunotoxicol. 2021 Jun;43(3):386-394. doi: 
      10.1080/08923973.2021.1924195. Epub 2021 May 20.